📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Inhibiting protein-protein interactions in the early stages of amyloid formation

Lead Research Organisation: University of Leeds
Department Name: Sch of Molecular & Cellular Biology

Abstract

In this project we focus on aggregation of Islet Associated PolyPeptide (IAPP) (type II diabetes) and A-beta (Alzheimer's). Increasing evidence suggests that the intrinsically disordered monomers of these proteins are in dynamic equilibrium with aggregation-prone oligomers. Despite significant progress in the characterization of IAPP/A-beta aggregation, mechanistic understanding of their folding/aggregation mechanisms remains obscure and new fundamental knowledge is needed to inform the design of therapies.

Objectives:
Combining native MS with biochemical/biophysical assays we will:
1. Explore how small molecule inhibitors affect IAPP/A-beta aggregation: using MS, IMS and kinetic assays (ThT fluorescence) we will screen for new small molecule inhibitors of aggregation using 'hits' recently discovered in SER's lab (Nature Chem (2015) and Nature Chem Biol (2016)). Using MS mapping with ETD (FS: Anal Chem (2016)) combined with other solution-based assays we will elucidate which species are responsible for interactions with different inhibitors and characterize inhibitor binding interfaces. We will then use cell biological assays to determine whether the inhibitors affect cytotoxicity.
2. Explore the sequence-dependence of aggregation: using a novel screen for aggregation developed in SER's laboratory (Nature Chem Biol (2016)) we will select IAPP/A-beta sequences with altered aggregation properties. We will then select for mutations that enhance/retard disease progression and thus, elucidate how these mutations perturb folding and aggregation.

Novelty/Timeliness:
To our knowledge the project will reveal the first atomistic insights into the energy landscapes of folding/aggregation. By focusing on peptides that are the causative agent of amyloid associated with type II diabetes/Alzheimer's the results will also have impact on human health today.

Experimental Approach:
We will utilize native MS to the full for the project, and combine this with chemical biology, biophysics and cell biology, offering the student training in a wide range of techniques. All methods are up and running, enabling the student to make rapid progress.

People

ORCID iD

Emily Byrd (Student)

Publications

10 25 50

Studentship Projects

Project Reference Relationship Related To Start End Student Name
BB/M011151/1 30/09/2015 29/09/2023
2270523 Studentship BB/M011151/1 30/09/2019 31/12/2023 Emily Byrd
BB/T007222/1 30/09/2020 29/09/2028
2270523 Studentship BB/T007222/1 30/09/2019 31/12/2023 Emily Byrd
NE/W503125/1 31/03/2021 30/03/2022
2270523 Studentship NE/W503125/1 30/09/2019 31/12/2023 Emily Byrd